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Introduction
Drugs used for prophylactic therapy of primary headaches
can cause undesirable effects with long-term treatment;
weight gain is often observed in clinical practice, which in
some cases can become a relevant problem. In the medical
literature, data on this side effect lack studies specifically
assessing this parameter and thus are only partial and not
always concordant [1–5].
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Abstract We conducted a study on
367 patients (86% female, 14% male;
mean age 37±15 years) suffering
from migraine with and without aura
and chronic tension-type headache to
evaluate the incidence of weight gain,
an undesirable side effect observed
during prophylactic therapy in prima-
ry headaches. Patients treated with
amitriptyline (20 and 40 mg), pizo-
tifen (1 mg), propranolol (80–160
mg), atenolol (50–100 mg), vera-
pamil (160–240 mg), valproate (600
mg) and gabapentin (900–1200 mg)
were evaluated after a period of 3
and 6 months. In particular, 89
patients were assessed (78% female,
22% male) at 6 months, of whom 10
were in treatment with amitriptyline
20 mg, 19 with amitriptyline 40 mg,
7 with pizotifen (1 mg), 13 with pro-
pranolol (80–160 mg), 4 with vera-
pamil (160 mg), 10 with valproate
(600 mg), 15 with atenolol (50 mg)
and 11 with gabapentin (900–1200
mg). The control group consisted of
97 patients with migraine (79%
female, 21% male; mean age 35±16
years) without indication for prophy-
lactic therapy. Weight variations ≥1
kg were considered. After 6 months
of therapy, the percentage of patients
with weight gain was 86% with pizo-
tifen (6/7; mean weight increase
4.4±2.5 kg), 60% with amitriptyline
20 mg (6/10; 3.1±1.6), 47% with
amitriptyline 40 mg (9/19; 5.4±2.7),
25% with valproate 600 mg (2/8,
3.0±2.8 kg), 25% with verapamil
(1/4, 2.5 kg), 20% with atenolol
(3/15, 1.7±0.6 kg), 9% with
gabapentin (1/11, 1.5 kg) and 8%
with propranolol (1/13; 6 kg). We
conclude that propranolol,
gabapentin, atenolol, verapamil and
valproate affect body weight in a
modest percentage of patients at 6
months. A greater mean weight gain
at 6 months was found in patients
treated with pizotifen, amitriptyline,
and, in one patient out of 13, with
propranolol.
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Materials and methods
Previously, we conducted a study on 367 patients (86% female,
16% male; mean age 37±15 years) suffering from migraine with-
out aura (MO), migraine with aura (MA) and chronic tension-
type headache (CTTH), classified according to IHS criteria [6],
to monitor weight variations during prophylactic therapy in rela-
tion to dose and type of drug, age, sex, initial body mass index
(BMI) and therapeutic efficacy [7].
The patients were selected on the basis of indications for
prophylactic therapy, BMI (between 18.5 and 30), and absence
of metabolic, endocrine and psychiatric diseases, or other con-
ditions or pathologies that could modify body weight. The
control group consisted of 97 (79% female, 21% male; mean
age 35±16 years) patients with migraine without indication for
prophylactic therapy.
For 89 patients the study was extended to 6 months in
monotherapy with the following drugs: amitriptyline (20 and
40 mg), pizotifen (1 mg), propranolol (80–160 mg), atenolol
(50–100 mg), verapamil (160–240 mg), valproate (600 mg)
and gabapentin (900–1200 mg). Weight variations ≥1 kg were
considered.
Results
The evaluation of weight variations after 3 months of
therapy revealed a greater percentage of weight gain in
the groups treated with flunarizine 10 mg (92%), fol-
lowed by pizotifen (65%), flunarizine 5 mg (56%) and
amitriptyline (40%); these were followed by propra-
nolol, valproate, verapamil and atenolol with percent-
ages between 5 and 20%. No significant differences
were observed related to sex, age, initial BMI and ther-
apeutic efficacy [7].
Eighty-nine patients (78% female, 22% male) were
treated for 6 months, of whom 10 were in treatment with
amitriptyline 20 mg, 19 with amitriptyline 40 mg, 7 with
pizotifen (1 mg), 13 with propranolol (80–160 mg), 4 with
verapamil (160 mg), 10 with valproate (600 mg), 15 with
atenolol and 11 with gabapentin. We do not yet have data
on flunarizine at six months.
After 6 months of therapy, the percentage of patients
with weight increase was 86% with pizotifen (6/7; mean
weight increase 4.4±2.5 kg), 60% with amitriptyline 20
mg (6/10; 3.1±1.6 kg), 47% with amitriptyline 40 mg
(9/19; 5.4±2.7 kg), 25% with verapamil (1/4, 2.5 kg),
20% with valproate 600 mg (2/10, 3.0±2.8 kg), 20% with
atenolol (3/15, 1.7±0.6 kg), 9% with gabapentin (1/11,
1.5 kg) and 8% with propranolol (1/13; 6 kg) (Figs. 1 and
2). The control group recorded an average weight varia-
tion of <1 kg.
Discussion
Most of the drugs used in the prophylactic therapy of pri-
mary headaches cause weight variations, according to the
type of drug involved. In our previous study [7], after just
3 months of therapy, pizotifen, flunarizine and amitripty-
line can induce weight gain in a considerable percentage
of patients, varying from 90 to 40% depending on the
type of drug, while propranolol, gabapentin, atenolol,
verapamil and valproate seem to have a lesser impact on
body weight.
This study on patients treated for 6 months shows a
further weight increase compared to 3 months in the
groups taking pizotifen and amitriptyline, a fact that was
also observed in one patient among the 13 treated with
propranolol. Valproate, verapamil, atenolol and
gabapentin do not cause further weight increase during
extended treatment (Figs. 1 and 2).
Fig. 1 Percent of patients with weight increase in the different
study groups at 3 and 6 months
Fig. 2 Mean weight increase (kg) in the proportion of patients gain-


























































































Verapamil, valproate, atenolol and gabapentin affect body
weight in a modest and stable percentage of patients at 3
and 6 months. Pizotifen and amitriptyline cause an addi-
tional weight increase at 6 months, to an average of 5.4,
4.4 and 3.1 kg for amitriptyline 40 mg, pizotifen and
amitriptyline 20 mg respectively.
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